

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6568409
<b>Application Number:</b>	10522528
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7494
<b>Title of Invention:</b>	Therapeutic foam
<b>First Named Inventor/Applicant Name:</b>	David Dakin Iorwerth Wright
<b>Customer Number:</b>	22852
<b>Filer:</b>	Brenda Lynn Danek/astrid blakemore
<b>Filer Authorized By:</b>	Brenda Lynn Danek
<b>Attorney Docket Number:</b>	07588.0081
<b>Receipt Date:</b>	03-DEC-2009
<b>Filing Date:</b>	27-APR-2006
<b>Time Stamp:</b>	18:43:31
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	EP1716871.PDF	2065660 2e5eda85e8183cea90833c1ebad9a25ac68 a655a	no	45

### Warnings:

### Information:

2	Foreign Reference	EP0586875.PDF	376963 74d742472a3c2475d94a0205f0598983488 b8e41	no	6
---	-------------------	---------------	--	----	---

**Warnings:**

**Information:**

3	Foreign Reference	EP0564505_AB.PDF	841183 932e62f4b020eeb554379a448df45ce65ad 58398	no	22
---	-------------------	------------------	--	----	----

**Warnings:**

**Information:**

4	Foreign Reference	GB2369996.PDF	956244 e20cc834c1569fb23b1603028158bc2baf5d 77e7	no	21
---	-------------------	---------------	--	----	----

**Warnings:**

**Information:**

5	Foreign Reference	WO04_047969_AB.PDF	907531 6ad188b35ea866c4457b6b637e799abe0c d3270e	no	21
---	-------------------	--------------------	--	----	----

**Warnings:**

**Information:**

6	Foreign Reference	WO03_013475_AB.PDF	668410 f4984273a108c39dc1db525b1fb3c4742ee 9bc6c	no	16
---	-------------------	--------------------	--	----	----

**Warnings:**

**Information:**

7	Foreign Reference	WO02_058834_AB.PDF	1005534 e0b54ad5c5d16272a83cd3cf020f73441db 7d420	no	21
---	-------------------	--------------------	---	----	----

**Warnings:**

**Information:**

8	Foreign Reference	WO00_78629.PDF	831512 596a687f6793534d4e0c43b20737777cf434 ff34	no	20
---	-------------------	----------------	--	----	----

**Warnings:**

**Information:**

9	Foreign Reference	WO97_13585.PDF	1177959 29029ea2f22522629e13f5f813ced2cbe485 2b20	no	25
---	-------------------	----------------	---	----	----

**Warnings:**

**Information:**

10	Foreign Reference	WO96_38180.PDF	1630964 96c9f1040e03678b7c42ed0e692b88b772e 49a82	no	35
----	-------------------	----------------	---	----	----

**Warnings:**

**Information:**

11	Foreign Reference	WO96_08227_AB.PDF	1261979 766cc323e4e5c42bd09bd47c6f0c8f578fe 117	no	30
----	-------------------	-------------------	---	----	----

**Warnings:**

**Information:**

12	Foreign Reference	WO93_05819.PDF	2249822 c1ad93af48f79502a5c1d133a025e1b56e31 9fe0	no	51
----	-------------------	----------------	---	----	----

**Warnings:**

**Information:**

13	Foreign Reference	WO92_11873_AB.PDF	663759 e3c32fb98100f0b7cab901349a755b44903 547bd	no	17
----	-------------------	-------------------	--	----	----

**Warnings:**

**Information:**

14	NPL Documents	ANON_NewDrugsAustralianPrescriber.PDF	354467 27478b2041c348025bc592cde64d2ca1f1b e00cc	no	4
----	---------------	---------------------------------------	--	----	---

**Warnings:**

**Information:**

15	NPL Documents	BARRY_AtmosphereWeatherClimate.pdf	261961 6c07dd31e8aba043e6c645d12f6e505d843 d62f4	no	2
----	---------------	------------------------------------	--	----	---

**Warnings:**

**Information:**

16	NPL Documents	CAPRINI_DirectFactorXInhibition.PDF	149456 61a9b454f9baf7f65f605cc5f3415e0d5d48fd1d	no	2
----	---------------	-------------------------------------	--	----	---

**Warnings:**

**Information:**

17	NPL Documents	CAPRINI_DVTProphylaxis.PDF	344727 9574bd1de9aba9655365e114b522a3813 179239	no	4
----	---------------	----------------------------	---	----	---

**Warnings:**

**Information:**

18	NPL Documents	CAVEZZI_DuplexGuidedSclerotherapy.PDF	1316139 801fa25683833e2b8bf2361138b0417c721f 981a	no	11
----	---------------	---------------------------------------	---	----	----

**Warnings:**

**Information:**

19	NPL Documents	ChartofMicrofoamPatentsandApplications.PDF	309365 b0f9df137cd602657a31c02dbdcc9f840c9e 19f3	no	1
----	---------------	--	--	----	---

**Warnings:**

**Information:**

20	NPL Documents	CHO_CarbonDioxideAngiography.PDF	1372863 ccc6319fe1bc4d0b2aa75a6289e662651ced29cf	no	17
----	---------------	----------------------------------	---	----	----

**Warnings:**

**Information:**

21	NPL Documents	COMEROTA_ManagementofAcuteDVT.PDF	174759 c731c3f7827cd1b4a23abe01bf13c04dfef1709	no	5
----	---------------	-----------------------------------	---	----	---

**Warnings:**

**Information:**

22	NPL Documents	ELIAS_IsThereaLeak.PDF	871920 1e779664471b5ff19b4c05dff49800f6d9e0c5e	no	12
----	---------------	------------------------	---	----	----

**Warnings:**

**Information:**

23	NPL Documents	FRONEK_TreatmentofSmallVeins.PDF	322229 823a8366177c86c43a3ed3819b531ccfd9ba5e06	no	7
----	---------------	----------------------------------	--	----	---

**Warnings:**

**Information:**

24	NPL Documents	FRULLINI_SclerosingFoam.PDF	1751548 b8f2f11b44e785830aeb940c3415e261aeb7f33a	no	14
----	---------------	-----------------------------	---	----	----

**Warnings:**

**Information:**

25	NPL Documents	GARCIA-MINGO_FoamMedicalSystemANew.PDF	488873 1cf00312fb62385df38b1ad9df464cacaa12238	no	6
----	---------------	--	---	----	---

**Warnings:**

**Information:**

26	NPL Documents	GIBSON_ProprietaryPolidocanolEndovenousMicrofoam.PDF	609961 feb045c5e47f23902b18ab088677cab91ce9f2d	no	4
----	---------------	--	---	----	---

**Warnings:**

**Information:**

27	NPL Documents	GILLETT_SideEffectsandComplications.PDF	135147 55afb5b9ac4a36f89f281ae0b7097e797661b1c7	no	4
----	---------------	---	--	----	---

**Warnings:**

**Information:**

28	NPL Documents	GUEX_TheFrenchPolidocanolRegistry.PDF	477979 832fc54f213531aa46e5e885232b389f22a8cd63	no	4
----	---------------	---------------------------------------	--	----	---

**Warnings:**

**Information:**

29	NPL Documents	HARPER_AdvancesinTherapyforVenuous.PDF	360757 e347af277f1db900112478de4585c95f5fb36fc	no	8
----	---------------	--	---	----	---

**Warnings:**

**Information:**

30	NPL Documents	HENRIET_HistoryofFoam.PDF	261678 6d50bbbf6210ca875634e72bd398e6128e088887	no	6
----	---------------	---------------------------	--	----	---

**Warnings:**

**Information:**

31	NPL Documents	HILL_ComparisonofSclerosantFoam.PDF	223931 7a61a1d3c1a908532d47857d7f5f961c48b86c0e	no	6
----	---------------	-------------------------------------	--	----	---

**Warnings:**

**Information:**

32	NPL Documents	HOHLER_ComparisonBetweenThreeDimensional.PDF	265487 7e792b7b40e0c008c9499fce5e0a15c9eeb6da17	no	6
----	---------------	--	--	----	---

**Warnings:**

**Information:**

33	NPL Documents	KING_HowSafeIsHigh.PDF	157029 bd70362c67ab6447c3609a4428fdff89233bb805	no	4
----	---------------	------------------------	--	----	---

**Warnings:**

**Information:**

34	NPL Documents	KRUSCH_InsuranceandCodingforPhlebology.PDF	338216 1ae9ed694c40dd47dfcf821ce88f01619315d052	no	10
----	---------------	--	--	----	----

**Warnings:**

**Information:**

35	NPL Documents	LUKE_TheManagementofRecurrentVaricose.PDF	352923 81bf8baae4d443bf0e7d4e9781dd201dd3c9be3	no	6
----	---------------	---	---	----	---

**Warnings:**

**Information:**

36	NPL Documents	MaterialSafetyDatasheet.PDF	229755 8e072a093c16dabf4c187df60aad42330d16d027	no	10
----	---------------	-----------------------------	--	----	----

**Warnings:**

**Information:**

37	NPL Documents	MEISSNER_PelvicVeinsandVascular.PDF	1254727 ca8eb721ba05c6b367a3da254fb33ed89f3d7d6b	no	13
----	---------------	-------------------------------------	---	----	----

**Warnings:**

**Information:**

38	NPL Documents	MORRISON_FoamSafetyStudies.PDF	329701 b05f6c68fab0c3ca34d1b539da43ec28e44bf fb1a	no	6
----	---------------	--------------------------------	---	----	---

**Warnings:**

**Information:**

39	NPL Documents	MORRISON_StrategiesforPreventingtheBig.PDF	408195 002ba4404655f/be99830b0c70077191aa98291b	no	9
----	---------------	--	--	----	---

**Warnings:**

**Information:**

40	NPL Documents	NEUHARDT_EmboliDetectionintheMCAConcurrent.PDF	202714 d4c691901bed6a5bb9cb55ad12c06e509730b730	no	7
----	---------------	--	--	----	---

**Warnings:**

**Information:**

41	NPL Documents	PITTALUGAP_TheComplexCase.PDF	256973 c899198fa990d8bfa56752e4ca7eda4a9cf58d12	no	5
----	---------------	-------------------------------	--	----	---

**Warnings:**

**Information:**

42	NPL Documents	PROEBSTLE_OneandTwoYears.PDF	63806 c993449c8f0d43119d10817e653a4161727b9012	no	3
----	---------------	------------------------------	---	----	---

**Warnings:**

**Information:**

43	NPL Documents	RABE_PolidocanolSodiumTetradecylSulfate.PDF	161524 620b12616e92a064729bb5e94bdc660bbe266da1	no	4
----	---------------	---	--	----	---

**Warnings:**

**Information:**

44	NPL Documents	RATHBUN_VenousThromboembolismTheProblem.PDF	127429 4a921d25a13a895f93f095fd8deae4ab36cf b2f9	no	4
----	---------------	---	--	----	---

**Warnings:**

**Information:**

45	NPL Documents	ROBERTSON_AStudyoftheLocal.PDF	308747 e7aabaea1bfd99881a86ccdf7d4760aebaa9399a	no	6
----	---------------	--------------------------------	--	----	---

**Warnings:**

**Information:**

46	NPL Documents	RUSH_NeurologicalandVisualSymptoms.PDF	429800 76de95e2da4a844e813950165477a7612575d243	no	3
----	---------------	--	--	----	---

**Warnings:**

**Information:**

47	NPL Documents	SADOUN_SclerosingFoamMaterialandMethods.PDF	520262 f1fbf63e0b809d5ee581f079ddcc26167590b07e	no	8
----	---------------	---	--	----	---

**Warnings:**

**Information:**

48	NPL Documents	SCHLIEPHAKE_ANewStandardizedDigital.PDF	225578 886d24debd5c0239e860a05ec03019e302a0c8a7	no	6
----	---------------	---	--	----	---

**Warnings:**

**Information:**

49	NPL Documents	SCHUL_CompressionTherapy_vs_Sclerotherapy.PDF	95792 de498517bd76c1079e9646f7278a8bf62bd47f5a	no	4
----	---------------	---	---	----	---

**Warnings:**

**Information:**

50	NPL Documents	SCHUL_InsuranceDenials.PDF	110272 e594150856fcfd32e76f8132f68026df786f43c	no	4
----	---------------	----------------------------	---	----	---

**Warnings:**

**Information:**

51	NPL Documents	SICA_UltrasoundAppearenceofSclerosing.PDF	286328 62f187803042fe3b45c11ec301ef7b23623749b4	no	4
----	---------------	---	--	----	---

**Warnings:**

**Information:**

52	NPL Documents	SLUTSKY_SclerotherapyComplicationsMatting.PDF	150164 4c96193303290bf76e390cd5877e86884e6b0482	no	4
----	---------------	---	--	----	---

**Warnings:**

**Information:**

53	NPL Documents	STOUGHTON_BasicSclerotherapy.PDF	788049 58d36a494d57cabd92325abf23c541be417d3cb5	no	14
----	---------------	----------------------------------	--	----	----

**Warnings:**

**Information:**

54	NPL Documents	TESSARI_TheTourbillonTurbulence.PDF	373956 1ec851a272ff5dbd9182e6d89d48d6a4bb304310	no	5
----	---------------	-------------------------------------	--	----	---

**Warnings:**

**Information:**

55	NPL Documents	WAKEFIELD_DiagnosisandManagementofPE.PDF	274744 4d068d37844c281e7ab74ec1826a0d0c88dc45bd	no	8
----	---------------	--	--	----	---

**Warnings:**

**Information:**

56	NPL Documents	WAKEFIELD_NewAnticoagulant.s.PDF	385317 007938999d2bdff6c75e8cc422582519c4bc6404	no	8
----	---------------	----------------------------------	--	----	---

**Warnings:**

**Information:**

57	NPL Documents	WRIGHT_ASingleCenterPilot.PDF	310018 3abbbe8a0e29837ef74b5658972c185d4e99012e	no	3
----	---------------	-------------------------------	--	----	---

**Warnings:**

**Information:**

58	NPL Documents	WRIGHT_TheVarisolveTrialWill.PDF	2151002 d4e89668c89847dfe61ce7a3c986d4430d5b5601	no	38
----	---------------	----------------------------------	---	----	----

**Warnings:**

**Information:**

59	NPL Documents	120309_EP04798564_Communication.pdf	250395 963e103355b0f493cbfb7a2d0d2787fe36945a7	no	5
----	---------------	-------------------------------------	---	----	---

**Warnings:**

**Information:**

60	NPL Documents	120309_EP04798564_Reply.pdf	435338 b4c61f5068df477f26ee47c9ff75618482e43771	no	8
----	---------------	-----------------------------	--	----	---

**Warnings:**

**Information:**

<b>Total Files Size (in bytes):</b>	35669521
-------------------------------------	----------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.